Logo
Nazad
Z. Velija-Ašimi, Azra Bureković, K. Dizdarevic
0 17. 4. 2014.

Long-term efficacy and withdrawal of octreotide LAR in acromegaly patients, a prospective single centre study with 4 years follow-up

In total 17 patients with acromegaly diagnosed at Endocrinology Clinic in Sarajevo, somatostatin sensitive (10 females and 6 males, age range 37-65 years, 6 patients with microadenoma and 10 patients with macroadenoma) were treated with octreotide LAR. Follow-up period was 4 years (2009-2014). Ten patients were treated with surgical and octreotide treatment. One patient was treated with surgical, octreotide and gamma-knife treatment and six patients were treated only with octreotide LAR. The concentration of human Growth Hormone (hGH) and Insulin-Like Growth Factor I (IGF-1) were evaluated before treatment and every 6 months during follow-up period of 4 years, while magnetic resonance imaging (MRI) was taken before the treatment and every year during follow-up period. Thirteen patients received octreotide 30 mg/28 days, two patient received 20 mg and other two 60 mg/28 days. Statistical data analysis includes basic statistics, descriptive statistics and nonparametric statistics (Friedman, Wilcoxon signed ranks test and Mann–Whitney U-test). Statistical significance was set as p < 0.05.Copy and paste your text content here, adjusting the font size to fit. Objective


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više